Sigyn Therapeutics (SIGY) Stock Statistics & Valuation Metrics

Sigyn Therapeutics has a market cap or net worth of $80.27K. The enterprise value is $2.81M.

Sigyn Therapeutics has 1,605,377 shares outstanding. The number of shares has decreased by -2.65% in one year.

Sigyn Therapeutics’s return on equity (ROE) is 0.75 and return on invested capital (ROIC) is 111.21%.

The current PE Ratio of Sigyn Therapeutics is ―. Sigyn Therapeutics’s PEG ratio is 0.04.

In the last 12 months, Sigyn Therapeutics had revenue of 0.00 and earned -3.34M in profits. Earnings per share was -2.51.

In the last 12 months, operating cash flow was -936.43K and capital expenditures -4.00, giving a free cash flow of -936.43K billion.

Sigyn Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Sigyn Therapeutics upcoming earnings date is ―, ―.

Sigyn Therapeutics as a current ratio of <0.01, with Debt / Equity ratio of -47.56%

In the past 12 months, Sigyn Therapeutics has paid 0.00 in taxes.

Sigyn Therapeutics EV to EBITDA ratio is -2.53, with an EV/FCF ratio of -7.31.

Sigyn Therapeutics has $85.57K in cash and marketable securities with $2.81M in debt, giving a net cash position of -$2.73M billion.

Gross margin is 26.39%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Sigyn Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―